HAYWARD, Calif.--(BUSINESS WIRE)--Mar. 8, 2018--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation platform, today announced that the Company will
report fourth quarter and full year 2017 financial results and
operational highlights on Friday, March 16th, 2018. Pulse Biosciences
management will host a conference call and webcast at 4:30 p.m. Eastern
Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing
(844) 494-0190 (domestic) and (508) 637-5580 (international) using the
conference ID# 1487908. The webcast of the conference call can be
accessed live on the Investor Relations section of the Pulse Biosciences
website, www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment based on the Nano-Pulse Stimulation (NPS)
platform, a proprietary cell signaling technology. NPS is a non-thermal,
precise, focal, drug-free tissue treatment technology that directly
affects the cell membrane and intracellular structures to stimulate
unique behaviors in cells. NPS can initiate a cell death process that
allows for the treatment of tissue cells with only a minimal
inflammatory response, which improves healing outcomes and supports the
replacement of treated tissue cells with healthy tissue cells. In
cancerous lesions, NPS has been shown in preclinical models to induce
immunogenic cell death (ICD), which exposes the unique antigens of the
treated cells to the immune system, results in the generation of
cytotoxic T-cells and mounts an adaptive immune response. Pulse
Biosciences is investigating a variety of applications for its
technology that exploits the technology’s unique biologic effect,
including immuno-oncology, dermatology, and veterinary medicine. More
information is available at www.pulsebiosciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180308006033/en/
Source: Pulse Biosciences, Inc.
Investor Relations:
Pulse Biosciences, Inc.
Brian Dow
Sr.
Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
The
Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam
Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com
